Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity
In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated with dismal prognosis. Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-ce...
Gespeichert in:
| Veröffentlicht in: | Blood Jg. 129; H. 16; S. 2246 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
20.04.2017
|
| Schlagworte: | |
| ISSN: | 1528-0020, 1528-0020 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated with dismal prognosis. Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-cell NHL, rituximab resistance remains an important obstacle to successful treatment of these tumors. To improve the efficacy of CD20-targeted therapy, we fused interleukin 21 (IL-21), which induces direct lymphoma cytotoxicity and activates immune effector cells, to the anti-CD20 antibody (αCD20-IL-21 fusokine). We observed substantially enhanced IL-21R-mediated signaling by the fusokine compared with native IL-21 at equimolar concentrations. Fusokine treatment led to direct apoptosis of lymphoma cell lines and primary tumors that otherwise were resistant to native IL-21 treatment. In addition to direct cytotoxicity, the fusokine enhanced NK cell activation, effector functions, and interferon γ production, resulting in greater antibody-dependent cell-mediated cytotoxicity compared with IL-21 and/or anti-CD20 antibody treatments. Further, the αCD20-IL-21 fusokine stabilizes IL-21 and prolongs its half-life. In vivo αCD20-IL-21 therapy resulted in a significant tumor control in the rituximab-resistant A20-huCD20 tumors. Collectively, the dual functional ability of the αCD20-IL-21 fusokine to induce direct apoptosis and activate immune effector cells may provide benefit over existing treatments for NHL. |
|---|---|
| AbstractList | In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated with dismal prognosis. Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-cell NHL, rituximab resistance remains an important obstacle to successful treatment of these tumors. To improve the efficacy of CD20-targeted therapy, we fused interleukin 21 (IL-21), which induces direct lymphoma cytotoxicity and activates immune effector cells, to the anti-CD20 antibody (αCD20-IL-21 fusokine). We observed substantially enhanced IL-21R-mediated signaling by the fusokine compared with native IL-21 at equimolar concentrations. Fusokine treatment led to direct apoptosis of lymphoma cell lines and primary tumors that otherwise were resistant to native IL-21 treatment. In addition to direct cytotoxicity, the fusokine enhanced NK cell activation, effector functions, and interferon γ production, resulting in greater antibody-dependent cell-mediated cytotoxicity compared with IL-21 and/or anti-CD20 antibody treatments. Further, the αCD20-IL-21 fusokine stabilizes IL-21 and prolongs its half-life. In vivo αCD20-IL-21 therapy resulted in a significant tumor control in the rituximab-resistant A20-huCD20 tumors. Collectively, the dual functional ability of the αCD20-IL-21 fusokine to induce direct apoptosis and activate immune effector cells may provide benefit over existing treatments for NHL.In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated with dismal prognosis. Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-cell NHL, rituximab resistance remains an important obstacle to successful treatment of these tumors. To improve the efficacy of CD20-targeted therapy, we fused interleukin 21 (IL-21), which induces direct lymphoma cytotoxicity and activates immune effector cells, to the anti-CD20 antibody (αCD20-IL-21 fusokine). We observed substantially enhanced IL-21R-mediated signaling by the fusokine compared with native IL-21 at equimolar concentrations. Fusokine treatment led to direct apoptosis of lymphoma cell lines and primary tumors that otherwise were resistant to native IL-21 treatment. In addition to direct cytotoxicity, the fusokine enhanced NK cell activation, effector functions, and interferon γ production, resulting in greater antibody-dependent cell-mediated cytotoxicity compared with IL-21 and/or anti-CD20 antibody treatments. Further, the αCD20-IL-21 fusokine stabilizes IL-21 and prolongs its half-life. In vivo αCD20-IL-21 therapy resulted in a significant tumor control in the rituximab-resistant A20-huCD20 tumors. Collectively, the dual functional ability of the αCD20-IL-21 fusokine to induce direct apoptosis and activate immune effector cells may provide benefit over existing treatments for NHL. In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated with dismal prognosis. Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-cell NHL, rituximab resistance remains an important obstacle to successful treatment of these tumors. To improve the efficacy of CD20-targeted therapy, we fused interleukin 21 (IL-21), which induces direct lymphoma cytotoxicity and activates immune effector cells, to the anti-CD20 antibody (αCD20-IL-21 fusokine). We observed substantially enhanced IL-21R-mediated signaling by the fusokine compared with native IL-21 at equimolar concentrations. Fusokine treatment led to direct apoptosis of lymphoma cell lines and primary tumors that otherwise were resistant to native IL-21 treatment. In addition to direct cytotoxicity, the fusokine enhanced NK cell activation, effector functions, and interferon γ production, resulting in greater antibody-dependent cell-mediated cytotoxicity compared with IL-21 and/or anti-CD20 antibody treatments. Further, the αCD20-IL-21 fusokine stabilizes IL-21 and prolongs its half-life. In vivo αCD20-IL-21 therapy resulted in a significant tumor control in the rituximab-resistant A20-huCD20 tumors. Collectively, the dual functional ability of the αCD20-IL-21 fusokine to induce direct apoptosis and activate immune effector cells may provide benefit over existing treatments for NHL. |
| Author | Rosenblatt, Joseph D Parvin, Salma Zhang, Yu Shin, Seung-Uon Cho, Hyun-Mi Timmerman, John M Kunkalla, Kranthi Bhatt, Shruti Lossos, Izidore S Vega, Francisco |
| Author_xml | – sequence: 1 givenname: Shruti surname: Bhatt fullname: Bhatt, Shruti organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center – sequence: 2 givenname: Salma surname: Parvin fullname: Parvin, Salma organization: Sheila and David Fuente Graduate Program in Cancer Biology, and – sequence: 3 givenname: Yu surname: Zhang fullname: Zhang, Yu organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center – sequence: 4 givenname: Hyun-Mi surname: Cho fullname: Cho, Hyun-Mi organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center – sequence: 5 givenname: Kranthi surname: Kunkalla fullname: Kunkalla, Kranthi organization: Department of Pathology, University of Miami Miller School of Medicine, Miami, FL; and – sequence: 6 givenname: Francisco surname: Vega fullname: Vega, Francisco organization: Department of Pathology, University of Miami Miller School of Medicine, Miami, FL; and – sequence: 7 givenname: John M surname: Timmerman fullname: Timmerman, John M organization: Division of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, CA – sequence: 8 givenname: Seung-Uon surname: Shin fullname: Shin, Seung-Uon organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center – sequence: 9 givenname: Joseph D surname: Rosenblatt fullname: Rosenblatt, Joseph D organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center – sequence: 10 givenname: Izidore S surname: Lossos fullname: Lossos, Izidore S organization: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28137826$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAQRS0EoqXwBwh5ycYwM3m5y1KeooINrCsnmVSG1A6xg-jf0wqQWN2jqzOj0RyJfecdC3GKcIGo6bJsva8VAeYKpqpINCHuiTFmpBUAwf4_HomjEN4AME0oOxQj0pgUmvKxCDMXrZpfEyjrIvctD-_WKULZDMFvkWU0_YpjkGvT2pUzLsorWXHbBvlpjaxtz1WUpvNd9MEGaVwtnx7VzlA1d-xq3o5Um-ij_7KVjZtjcdCYNvDJb07E6-3Ny_xeLZ7vHuazhapS0FEV0DSZThKEghKgmrA0GZg00QXWaKptX3CuWWORVk3alGmWMZhS5zDFCokm4vxnb9f7j4FDXK5t2N1lHPshLFHnCRHQFLbq2a86lGuul11v16bfLP8eRd95lW1D |
| CitedBy_id | crossref_primary_10_1016_j_bbcan_2021_188526 crossref_primary_10_1038_s41573_023_00746_x crossref_primary_10_3389_fimmu_2023_1090311 crossref_primary_10_1007_s00259_018_4214_x crossref_primary_10_1016_j_intimp_2024_112600 crossref_primary_10_1093_abt_tbab014 crossref_primary_10_3389_fimmu_2020_621225 crossref_primary_10_3389_fimmu_2024_1369743 crossref_primary_10_1016_j_addr_2018_09_002 crossref_primary_10_1016_j_mucimm_2024_10_003 crossref_primary_10_1182_blood_2017_02_767541 crossref_primary_10_1016_j_it_2019_01_001 crossref_primary_10_1038_s41419_018_1259_5 crossref_primary_10_1016_j_addr_2022_114112 crossref_primary_10_1016_j_molmed_2025_01_010 crossref_primary_10_1002_adhm_202002214 crossref_primary_10_1038_s41467_024_54877_9 crossref_primary_10_3389_fimmu_2023_1267621 crossref_primary_10_1016_j_bbcan_2024_189084 crossref_primary_10_1016_j_intimp_2021_108307 crossref_primary_10_1016_j_apsb_2024_07_024 crossref_primary_10_3389_fimmu_2022_1021828 crossref_primary_10_1016_j_intimp_2022_109634 |
| ContentType | Journal Article |
| Copyright | 2017 by The American Society of Hematology. |
| Copyright_xml | – notice: 2017 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2016-09-738211 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 28137826 |
| Genre | Journal Article |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c408t-70ff58331072302d21ba50a43871d1ac1077e68e8174cf4fb455e0ab86091c122 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 28 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000399565300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Thu Oct 02 12:42:35 EDT 2025 Wed Feb 19 02:30:37 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Language | English |
| License | 2017 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c408t-70ff58331072302d21ba50a43871d1ac1077e68e8174cf4fb455e0ab86091c122 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://ashpublications.org/blood/article-pdf/129/16/2246/1399797/blood738211.pdf |
| PMID | 28137826 |
| PQID | 1863220290 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1863220290 pubmed_primary_28137826 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-04-20 20170420 |
| PublicationDateYYYYMMDD | 2017-04-20 |
| PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2017 |
| References | 28428235 - Blood. 2017 Apr 20;129(16):2209-2210 |
| References_xml | – reference: 28428235 - Blood. 2017 Apr 20;129(16):2209-2210 |
| SSID | ssj0014325 |
| Score | 2.382169 |
| Snippet | In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2246 |
| SubjectTerms | Animals Antibodies, Monoclonal, Murine-Derived - genetics Antibodies, Monoclonal, Murine-Derived - immunology Antigens, CD20 - genetics Antigens, CD20 - immunology Antineoplastic Agents - immunology Antineoplastic Agents - metabolism Antineoplastic Agents - pharmacokinetics Apoptosis - drug effects B-Lymphocytes - drug effects B-Lymphocytes - immunology B-Lymphocytes - pathology Cytotoxicity, Immunologic - drug effects Gene Expression Half-Life Humans Interferon-gamma - biosynthesis Interferon-gamma - immunology Interleukins - genetics Interleukins - immunology Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Killer Cells, Natural - pathology Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - genetics Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - pathology Mice Mice, Inbred BALB C Mice, Transgenic Molecular Targeted Therapy Receptors, Interleukin-21 - genetics Receptors, Interleukin-21 - immunology Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - pharmacokinetics Signal Transduction |
| Title | Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28137826 https://www.proquest.com/docview/1863220290 |
| Volume | 129 |
| WOSCitedRecordID | wos000399565300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB6VAm0vLV1ooQ9kpKo3C9txEu8JLdsiJMSKA0h7Wzl-oAhItjiLuv--4zzEqVKlXiIrShRrPJn55mF_AN-sMoVBP0id0YYiAsd_jntJjR8LZn2E9KYlm8hnMzWfj6_6hFvo2yoHm9gaalubmCM_5ipD3WNizE6Wv2hkjYrV1Z5CYwM2E4QyUavz-XMVQSYt6Sq6KEUjLuq3ziGkPu7awtH7ZbH4nydKcP53kNk6m7N3_zvNHXjbw0wy6fTiPbxw1Qh2JxWG2A9r8p20jZ9tRn0E26fD6PV0oH8bwavLvuq-C2FSNSWd_sAQMJ4u8XjvVndlRQUnfhVqHDrSNZQH8oCw_jb21pBTEmsCgTyVmnR-k-hlvWzqUAaiK0tmFzQ-QQca3oaYdVM39W_8arPeg5uzn9fTc9qTNVAjmWpozryPO7gwnMSoRljBC50yLROMyCzXBu_nLlNOYQhkvPSFTFPHdKEyRCyGC_EBXlZ15faBpNZIIYrUKpvJIpfKOpPkrMgiNbKR8gCOBtkvUChxrrpy9SosnqV_AB-7BVwsu1M7FkLxBOFQ9ukf3v4Mb0R030yiinyBTY-mwH2FLfPUlOHxsNUyvM6uLv8AP6Ta6Q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-CD20-interleukin-21+fusokine+targets+malignant+B+cells+via+direct+apoptosis+and+NK-cell-dependent+cytotoxicity&rft.jtitle=Blood&rft.au=Bhatt%2C+Shruti&rft.au=Parvin%2C+Salma&rft.au=Zhang%2C+Yu&rft.au=Cho%2C+Hyun-Mi&rft.date=2017-04-20&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=129&rft.issue=16&rft.spage=2246&rft_id=info:doi/10.1182%2Fblood-2016-09-738211&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |